2.08Lab to company: IP, tech transfer and spinouts

Royalties, milestones, equity in lieu and anti-stacking

Stage: Minus-oneDeeptech

Core idea#

A university or lab licence (playbook 2.07) has a set of economic terms: what the company pays, when, and for what. Founders tend to fixate on the royalty rate. Investors look at the whole package : upfront fees, annual payments, milestones, royalties, the share of sublicensing income, patent cost reimbursement and equity. Each term moves money at a different time, and the timing matters more than the headline rate for a startup that won't have revenue for years.

The principles:

  1. Pay later, not now. Cash before revenue is the most expensive money a startup spends. Favour terms that bite when the company can pay.
  2. Trade terms against each other. Universities often accept lower royalties for equity, or lower upfront fees for later milestones.
  3. Model the total burden on a real product, including other licences you'll need. A 3% royalty that's fine alone can be fatal stacked with three others.
  4. Know the benchmarks for your sector and country, so you can tell a fair offer from an outlier.

Who it's for: founders negotiating or reviewing a licence, option or assignment from a university, institute or government lab.

Benchmarks#

United States#

Gunderson Dettmer's analysis of university licences to venture-backed startups found (Gunderson Dettmer, 2024):

  • Royalty: median 2.38% where the licence has an anti-stacking clause, 1.75% where it doesn't; royalties are usually on net sales and often tiered.
  • Anti-stacking: present in 65% of licences, typically letting the licensee reduce its royalty by 50% of amounts paid to third parties, down to a 50% floor. Sublicensing income: shared with the university in 94% of licences.
  • Equity: average grant 4.00%, with anti-dilution protection in 83% of licences with equity, typically until about $10 million is raised.

Published "express" licences show typical shapes. Cornell's FastTrack licence for medical devices offers 2.5% of net sales without anti-stacking, or 4% with anti-stacking (potentially down to 2%), milestones of $75,000 at regulatory clearance and $150,000 at $30 million cumulative sales, and annual fees starting at year five (Cornell). Tulane's licence for therapeutics and devices offers 2% of net sales without anti-stacking or 3% with, and either 15% of non-royalty sublicence income with royalty pass-through or 25% of all sublicence income without (Tulane).

Across fields, reported university royalty rates span roughly 1% to 10% of net sales, with low-to-mid single digits most typical for an early-stage invention (CASRAI).

United Kingdom#

The USIT Guide, developed by leading UK university TTOs and investors, proposed a landing zone of 10% to 25% university equity and a 0% to 5% royalty depending on the technology's maturity (Cambridge Enterprise). For software spinouts, the USIT for Software Guide recommends 5% to 10% university equity and 0% to 2% royalties (Imperial College). Average UK university stakes fell to 16% for deals in 2024–25 (20% life sciences, 14% hardware) (CASRAI on RAEng).

India#

Terms are set by each institute's IP and startup policy, and often combine a small equity stake with a royalty or revenue share, sometimes letting founders choose between them. For example, IIT Kanpur's faculty policy has offered liability-free equity in return for permission to use institute IP (IIT Kanpur), and newer policies (such as IIT Kharagpur's 2026 policy) set specific equity-based licensing options (playbook 2.11). Ask your institute for its current schedule; many are negotiable for spinouts.

Each term, and what to ask for#

Term What it is Startup-friendly version
Upfront licence fee A one-off payment at signing Small or zero; deferred to the
first financing or replaced by
equity
Term What it is Startup-friendly version
Patent cost
reimbursement		 Repaying the institution's
past patent costs, and paying
future ones		 Past costs deferred or paid in
instalments; future costs
limited to agreed countries
(2.05)
Annual fee or minimum
royalty		 A yearly payment, often
creditable against royalties		 Zero for the first 3–5 years,
then modest, and creditable
against royalties
Milestone payments Paid on events: financing,
regulatory approval, first sale,
sales thresholds		 Tied to events that bring cash
in (a sales threshold, an
approval), not to time
Running royalty A percentage of net sales of
licensed products		 Low single digits; tiered; on
the licensed component, not
the whole system; with anti-
stacking
Sublicence income share The institution's share of what
you earn by sublicensing		 A declining share over time or
as the company adds value;
exclude investment and R&D
funding
Equity Shares for the institution in
place of some cash terms		 Small, with anti-dilution only
up to a modest funding
threshold, ending at the first
priced round
Change-of-control or
assignment fee		 Payment if the company is
sold or the licence transferred		 Avoid, or keep small and fixed
(playbook 2.09)

Definitions that matter more than the rate#

  • "Net sales": sales minus returns, discounts, taxes, freight and similar deductions. Check what's deducted.
  • "Licensed product": only products covered by a valid claim of the licensed patents, or anything "using" the technology? The narrower, the better for the company. Royalty base for systems: if the patent covers one component of a larger system, royalty should apply to the component's value (or a reduced rate), not the whole system price.
  • Royalty term: royalties should end when the last valid patent claim covering the product expires in that country.

Equity in lieu#

Many institutions take equity instead of some cash, which suits cash-poor startups. Points to agree:

  • The amount and whether it replaces royalties, fees or both (2.11).
  • Anti-dilution: universities often ask to keep their percentage until a funding threshold; Gunderson's data shows a median threshold of about $10 million (Gunderson Dettmer). Keep it low and time-limited; it dilutes the founders.
  • Rights: standard minority rights only; no special vetoes.

Anti-stacking and the total royalty burden#

What stacking is#

A product often needs several licences: the core university patent, a second university's patent on a component, a commercial licence for a manufacturing step. Each takes a royalty. Together they can exceed what the product's margin can bear.

What an anti-stacking clause does#

It lets you reduce the royalty you pay one licensor by part of what you pay others for IP you need, usually down to a floor. A common US version lets the licensee cut the university royalty by 50% of third-party royalties, but by no more than half (Gunderson Dettmer; Goodwin). Universities sometimes set a higher headline rate in return, as the Cornell and Tulane licences show.

A rule of thumb for checking the burden#

One long-standing heuristic is that a licensor should get about a quarter of the product's profit: with a 20% profit margin, a 5% royalty (Guide to Biotech Startups). Courts no longer accept the "25% rule" as a method, but it remains a quick sense check of whether the total burden leaves room for a business.

Worked example (illustrative)#

A medical device company will sell a monitor at $10,000 with a 60% gross margin and a 15% operating margin at scale. It needs three licences:

Licensor Headline
royalty		 With anti-stacking
University A (core sensor patent) 4% Reduced by 50% of other royalties,
floor 2%
University B (signal-processing
patent)		 2% No anti-stacking
Company C (coating process) 1.5% No anti-stacking
  • Without anti-stacking: 4% + 2% + 1.5% = 7.5% of net sales, which is half the operating margin.
  • With University A's clause: other royalties total 3.5%, so A's royalty falls by 1.75 points, to 2.25% (above the 2% floor). Total: 2.25% + 2% + 1.5% = 5.75% .

The company also negotiates for A's royalty to apply only to the sensor module (valued at 40% of the device price), not the whole monitor. A's effective rate on the device becomes 2.25% × 40% = 0.9%, and the total burden falls to about 4.4% of device net sales. Investors find that much easier to accept.

Negotiating scripts#

Moving cash to later#

"We can't pay a meaningful upfront fee before we've raised. Could we replace it with a payment due at our first priced round, or a slightly higher milestone at first commercial sale? That way you're paid when there's money to pay with."

Asking for anti-stacking#

"Our product will likely need [N] other licences, including [examples]. Without an anti-stacking clause the total royalty could reach [X]%, which investors will see as a risk. Could we include the standard 50% offset with a floor? We'd accept a slightly higher headline rate in return."

Narrowing the royalty base#

"The patent covers the sensor, which is about 40% of the device's value. Could the royalty apply to the sensor module's value, or be set at a rate that reflects that share?"

Trading royalty for equity#

"We'd prefer to give you more upside through equity and keep the running royalty low, because royalties reduce our margin for the life of the product. Would [X]% equity with a [Y]% royalty work instead of [Z]% royalty alone?"

Common mistakes#

  • Negotiating the royalty rate in isolation. Model the whole package and the timing. Agreeing early annual minimums that drain cash before revenue.
  • Royalty on the whole system when the patent covers one part.
  • No anti-stacking in a field where you'll need several licences.
  • Broad "licensed product" definitions that charge royalties on things the patent doesn't cover.
  • Sublicence income definitions that include investment money or research funding. Long anti-dilution for the university's equity.
  • Not checking published express licences for your institution; they show what's normal.
  • 2.03 Working with the tech transfer office
  • 2.07 Licence anatomy
  • 2.09 Sublicensing and change of control
  • 2.10 Negotiating with a university
  • 2.11 Spinout equity norms

Sources#

Worked example is illustrative. Not legal advice. Last checked November 2026.

← 2.07 Licence anatomy, clause by clause2.09 Sublicensing and change-of-control clauses →